-
-
Call more information
660-596-2224 -
Authors: Richard Simoneaux; Steven L. Shafer, MD, FASA ASA Monitor January 2023, Vol. 87, 1–8. During the first two years of the pandemic, SARS-CoV-2 steadily evolved. The ancestral Wuhan strain gave way to the Alpha variant, followed by Beta, Gamma, and Delta variants, each more infectious than the last (ASA Monitor 2021;85:1-7). A year ago, the ultra-infectious […]
Read MoreAuthor: Hannah Viroslav, BA, MD ASA Monitor January 2023, Vol. 87, 35. The style of medical writing that residents are exposed to, both in medical school and throughout training, revolves around the many. We are taught to think in terms of evidence-based medicine – and with evidence, the power is in the numbers. Most literally, a […]
Read MoreAuthors:Hasushita, Yudai MD et al A & A Practice 16(9):p e01616, September 2022. Remimazolam is a recently approved benzodiazepine sedative. We report a case of a 72-year-old man who experienced a cardiac arrest due to severe anaphylaxis immediately after general anesthesia induction. Based on the results of skin tests, including those for dextran 40, an […]
Read MoreAuthors: Nicholas L. McKenzie, B.S.P.H. et al Anesthesiology January 2023, Vol. 138, 42–54. Background Perioperative β-blocker therapy has been associated with increased risk of stroke. However, the association between β-blocker initiation before the day of surgery and the risk of stroke is unknown. The authors hypothesized there would be no association between preoperative β-blocker initiation within […]
Read MoreAuthor: Paul Pomerantz, FACHE ASA Monitor January 2023, Vol. 87, 12. Happy New Year! As I write this, it is mid-November, and I am always amazed at how quickly the end of year comes upon us. At ASA, it is a busy time: annual meeting reconciliation and follow-up, membership renewals, performance reviews, end-of-year accounting, implementation of […]
Read More